Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OAB-14 is a Bexarotene derivative that improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal(EAL) pathway in APP/PS1 transgenic mice [1] [2].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 226,000 |
50 mg | 約6-8 週間 | ¥ 294,000 |
100 mg | 約6-8 週間 | ¥ 445,500 |
説明 | OAB-14 is a Bexarotene derivative that improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal(EAL) pathway in APP/PS1 transgenic mice [1] [2]. |
In vivo | OAB-14 significantly improves cognitive function in amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mice when administered for either 15 days or 3 months, by promoting microglia phagocytosis, enhancing IDE and NEP levels, and reducing Aβ by 71%. This compound mitigates Aβ-induced pathological outcomes, including synaptic degeneration, neuronal loss, tau hyperphosphorylation, and neuroinflammation, without adversely affecting body weight or causing liver toxicity, even after prolonged use. Furthermore, OAB-14 boosts receptor-mediated endocytosis and normalizes autophagy flux through the AMPK/mTOR pathway, increasing lysosomal activity and decreasing Aβ accumulation in lysosomes of treated AD mice. |
別名 | OAB 14, OAB14 |
分子量 | 518.73 |
分子式 | C32H46N4O2 |
CAS No. | 2140911-49-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
OAB-14 2140911-49-3 OAB 14 OAB14 Inhibitor inhibitor inhibit